Pre-made Siltuximab benchmark antibody ( Whole mAb, anti-IL6 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-520
Anti-IL6 therapeutic antibody (Pre-made Siltuximab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Siltuximab (INN, trade name Sylvant; also known as CNTO 328, anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse proteins) monoclonal antibody. It binds to interleukin-6. Siltuximab has been investigated for the treatment of neoplastic diseases: metastatic renal cell cancer, prostate cancer, and Castleman's disease, among other types of cancer.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL6 therapeutic antibody (Pre-made Siltuximab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Centocor Inc;Janssen Biotech;Memorial Sloan-Kettering Cancer Center|
|Conditions Approved||Giant lymph node hyperplasia|
|Conditions Active||Multiple myeloma|
|Conditions Discontinued||Paraproteinaemia;Myelodysplastic syndromes;Non-Hodgkin's lymphoma;Prostate cancer;Renal cell carcinoma|